Embecta (EMBC) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
STAAR Surgical (STAA) has outperformed Embecta (EMBC) over the past year, losing 16.3% versus a loss of 57.1%. STAAR Surgical is the larger company by market cap ($1.12 billion vs $328.6 million), about 3.4 times the size. On valuation, Embecta trades at a lower forward P/E (3.3x vs 20.0x for STAAR Surgical).
Embecta pays a dividend yielding 7.93%, while STAAR Surgical does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMBC | STAA |
|---|---|---|
| Share price | $5.80 | $22.25 |
| Market cap | $328.63M | $1.12B |
| 1-day change | -1.86% | -0.49% |
| YTD return | -50.25% | -3.16% |
| 1-year return | -57.11% | -16.32% |
| 5-year return | — | -80.54% |
| P/E ratio (TTM) | 3.95 | 278.13 |
| Forward P/E | 3.29 | 20.02 |
| EPS (TTM) | $1.47 | $0.08 |
| Dividend yield | 7.93% | 0.00% |
| Annual dividend | $0.46 | $0.00 |
| 52-week high | $14.91 | $35.87 |
| 52-week low | $2.77 | $15.59 |
| Distance from 52-week high | -61.10% | -37.97% |
| Analyst consensus | none | buy |
| Avg. price target upside | -31.03% | +25.84% |
| Average volume | 1.37M | 998.64K |
| Shares outstanding | 56.66M | 50.14M |
| Employees | 1,850 | 921 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAAR Surgical is about 3.4 times larger than Embecta by market value ($1.12B vs $328.63M).
- STAA has outperformed EMBC by 40.8 percentage points over the past year.
- STAAR Surgical trades at a higher earnings multiple (278.1x vs 3.9x trailing P/E).
- Embecta offers a meaningfully higher dividend yield (7.93% vs 0.00%).
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Health Care · Medical/Dental Instruments · 1,850 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
EMBC vs STAA FAQ
Which is bigger, Embecta or STAAR Surgical?
STAAR Surgical (STAA) is larger, with a market capitalization of $1.12B compared with $328.63M for Embecta (EMBC).
Which stock has performed better over the past year, EMBC or STAA?
STAA returned -16.32% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EMBC or STAA?
EMBC has the lower trailing P/E at 3.9, versus 278.1 for STAA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Embecta or STAAR Surgical?
Embecta pays a dividend yielding 7.93%, while STAAR Surgical does not currently pay a regular dividend.
Are Embecta and STAAR Surgical in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Embecta and Ophthalmic Goods for STAAR Surgical.